Revolutionizing human papillomavirus (HPV)‐related cancer therapies: unveiling the promise of proteolysis targeting chimeras (PROTACs) and proteolysis targeting antibodies (PROTABs) in cancer nano‐vaccines

Personalized cancer immunotherapies, combined with nanotechnology (nano‐ vaccines), are revolutionizing cancer treatment strategies, explicitly targeting Human papilloma virus (HPV)‐related cancers. Despite the availability of preventive vaccines, HPV‐related cancers remain a global concern. Personalized cancer nano‐vaccines, tailored to an individual's tumor genetic mutations, offer a unique and promising solution. Nanotechnology plays a critical role in these vaccines by efficiently delivering tumor‐specific antigens, enhancing immune responses, and paving the way for precise and targeted therapies. Recent advancements in preclinical models have demonstrated the potential of polymeric nanoparticles and high‐density lipoprotein‐mimicking nano‐discs in augmenting the efficacy of personalized cancer vaccines. However, challenges related to optimizing the nano‐carrier system and ensuring safety in human trials persist. Excitingly, the integration of nanotechnology with Proteolysis‐ Targeting Chimeras (PROTACs) provides an additional avenue to enhance the effectiveness of personalized cancer treatment. PROTACs selectively degrade disease‐causing proteins, amplifying the impact of nanotechnology‐based therapies. Overcoming these challenges and leveraging the synergistic potential of nanotechnology, PROTACs, and Proteolysis‐Targeting Antibodies hold great promise in pursuing novel and effective therapeutic solutions for individuals affected by HPV‐related cancers.